Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab rechallenge with or without chemotherapy in third-line RAS wild-type metastatic colorectal cancer
MOH_2017-10-03_000748Phase 2Not yet recruiting
- Sponsor
- ד"ר אביעד זיק
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by ד"ר אביעד זיק. Primary endpoint: Efficacy of cetuximab rechallenge. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on MOH_2017-10-03_000748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-10-03_000748.